All In Biotech

Drug Trial Radar · NCT03412292

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 1, 2018

Primary completion

Nov 1, 2022

Study completion Dec 1, 2022

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
Jan 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).

Conditions

  • Acute Myelogenous Leukemia (AML)

Interventions

  • MAX-40279Drug

    MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S. MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light. MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: 8 weeks
  2. Maximum tolerated dose (MTD)Time frame: 4 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincent's Hospital Sydney Limited

    Darlinghurst, New South Wales, Australia · Recruiting

  • Western NSW Local Health District

    Dubbo, New South Wales, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.